Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25542854 | 0.90 | FOLH1 (0.58) | ALBFOLH1NOD1GLP1REPHX2 | |
| SCHEMBL23451113 | 0.89 | FOLH1 (0.63) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL25542879 | 0.86 | NOD1 (0.65) | ALBFOLH1NOD1GLP1REPHX2 | |
| SCHEMBL13286041 | 0.83 | ALB (0.62) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL29617648 | 0.83 | NOD1 (0.51) | ALBFOLH1NOD1GLP1REPHX2 | |
| SCHEMBL13335144 | 0.82 | FOLH1 (0.55) | FOLH1EPHX2 | |
| SCHEMBL13236367 | 0.82 | ALB (0.60) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL25548851 | 0.81 | FOLH1 (0.60) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL14073945 | 0.80 | KDM4E (0.57) | EPHX2 | |
| SCHEMBL13376980 | 0.80 | RECQL (0.61) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | ALB 2473/4885FOLH1 677/4885NOD1 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.